{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,25]],"date-time":"2026-06-25T12:09:45Z","timestamp":1782389385115,"version":"3.54.5"},"reference-count":18,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2023,9,18]],"date-time":"2023-09-18T00:00:00Z","timestamp":1694995200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,9,18]],"date-time":"2023-09-18T00:00:00Z","timestamp":1694995200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Region Stockholm","award":["FoUI-961732"],"award-info":[{"award-number":["FoUI-961732"]}]},{"name":"Region Stockholm","award":["FoUI-973659"],"award-info":[{"award-number":["FoUI-973659"]}]},{"DOI":"10.13039\/501100008364","name":"Stiftelsen Johanna Hagstrand och Sigfrid Linn\u00e9rs Minne","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100008364","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Japanese Swedish Research Foundation","award":["2022-PHJ537"],"award-info":[{"award-number":["2022-PHJ537"]}]},{"name":"Japanese Swedish Research Foundation","award":["2021-XET421"],"award-info":[{"award-number":["2021-XET421"]}]},{"DOI":"10.13039\/501100006313","name":"Barncancerfonden","doi-asserted-by":"publisher","award":["TJ2021-0125"],"award-info":[{"award-number":["TJ2021-0125"]}],"id":[{"id":"10.13039\/501100006313","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002794","name":"Cancerfonden","doi-asserted-by":"publisher","award":["22 2451 Fk"],"award-info":[{"award-number":["22 2451 Fk"]}],"id":[{"id":"10.13039\/501100002794","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004047","name":"Karolinska Institute","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100004047","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["World J Urol"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Purpose<\/jats:title>\n                <jats:p>The prognosis of upper urinary tract urothelial carcinoma (UTUC) is associated with tumour grade (G) and stage. Despite preoperative risk stratification and radical treatment, recurrence and progression are common. Thus, prognostic and monitoring biomarkers are needed. This feasibility study aimed to investigate if targeted analyses on circulating tumour DNA (ctDNA) in plasma could identify tumour-specific gene variants, and thus have potential for further evaluation as a biomarker in UTUC.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>Nine UTUC patients with genetically characterised tumours were included in this prospective pilot study. Two tumour-specific variants were chosen for targeted analyses with multiplex droplet digital PCR on cell-free DNA (cfDNA) from plasma at diagnosis or from recurrence.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Of six patients with diagnostic plasma samples, ctDNA was detected in four with G2 or G3 tumours and tumours\u2009&gt;\u2009300m<jats:sup>2<\/jats:sup> in size. Three of these patients progressed in their disease and the fourth had the largest G3 tumour at sampling. In contrast, the two patients with undetectable ctDNA in diagnostic plasma had a G1 tumour and G3 carcinoma in situ (CIS), respectively. The patient with G3 CIS had detectable ctDNA later during follow-up and progressed thereafter with aggressive intravesical recurrence and CT-scan-verified CIS progression in the upper urinary tract. In three patients with small recurrent G1 or G2 tumours, none had detectable ctDNA in plasma and all were progression free.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>Our early findings demonstrate that ctDNA in plasma can be detected by targeted analysis in patients with UTUC. However, further studies are needed to determine its role as a potential biomarker.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1007\/s00345-023-04583-w","type":"journal-article","created":{"date-parts":[[2023,9,18]],"date-time":"2023-09-18T12:02:11Z","timestamp":1695038531000},"page":"3421-3427","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Patient-specific targeted analysis of circulating tumour DNA in plasma is feasible and may be a potential biomarker in UTUC"],"prefix":"10.1007","volume":"41","author":[{"given":"Ninni","family":"Mu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cecilia","family":"Jylh\u00e4","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomas","family":"Axelsson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Filip","family":"Syd\u00e9n","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marianne","family":"Brehmer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6079-164X","authenticated-orcid":false,"given":"Emma","family":"Tham","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,9,18]]},"reference":[{"key":"4583_CR1","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1186\/s12894-021-00876-7","volume":"21","author":"A Soualhi","year":"2021","unstructured":"Soualhi A, Rammant E, George G, Russell B, Enting D, Nair R, Van Hemelrijck M, Bosco C (2021) The incidence and prevalence of upper tract urothelial carcinoma: a systematic review. BMC Urol 21:110","journal-title":"BMC Urol"},{"key":"4583_CR2","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1016\/j.eururo.2020.05.042","volume":"79","author":"M Roupr\u00eat","year":"2021","unstructured":"Roupr\u00eat M, Babjuk M, Burger M, Capoun O, Cohen D, Comp\u00e9rat EM, Cowan NC, Dominguez-Escrig JL, Gontero P, Hugh Mostafid A et al (2021) European association of urology guidelines on upper urinary tract urothelial carcinoma: 2020 update. Eur Urol 79:62\u201379","journal-title":"Eur Urol"},{"key":"4583_CR3","doi-asserted-by":"publisher","first-page":"614","DOI":"10.1111\/j.1464-410X.2012.11068.x","volume":"110","author":"ML Cutress","year":"2012","unstructured":"Cutress ML, Stewart GD, Zakikhani P, Phipps S, Thomas BG, Tolley DA (2012) Ureteroscopic and percutaneous management of upper tract urothelial carcinoma (UTUC): systematic review. BJU Int 110:614\u2013628","journal-title":"BJU Int"},{"key":"4583_CR4","doi-asserted-by":"publisher","first-page":"793","DOI":"10.1016\/j.ccell.2021.05.008","volume":"39","author":"Y Fujii","year":"2021","unstructured":"Fujii Y, Sato Y, Suzuki H, Kakiuchi N, Yoshizato T, Lenis AT, Maekawa S, Yokoyama A, Takeuchi Y, Inoue Y et al (2021) Molecular classification and diagnostics of upper urinary tract urothelial carcinoma. Cancer Cell 39:793-809.e798","journal-title":"Cancer Cell"},{"key":"4583_CR5","doi-asserted-by":"publisher","first-page":"1754","DOI":"10.1056\/NEJMra1706174","volume":"379","author":"RB Corcoran","year":"2018","unstructured":"Corcoran RB, Chabner BA (2018) Application of cell-free DNA analysis to cancer treatment. N Engl J Med 379:1754\u20131765","journal-title":"N Engl J Med"},{"key":"4583_CR6","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1111\/joim.12897","volume":"286","author":"G Barbany","year":"2019","unstructured":"Barbany G, Arthur C, Lied\u00e9n A, Nordenskj\u00f6ld M, Rosenquist R, Tesi B, Wallander K, Tham E (2019) Cell-free tumour DNA testing for early detection of cancer - a potential future tool. J Intern Med 286:118\u2013136","journal-title":"J Intern Med"},{"key":"4583_CR7","doi-asserted-by":"publisher","first-page":"2115","DOI":"10.1002\/cncr.31314","volume":"124","author":"N Agarwal","year":"2018","unstructured":"Agarwal N, Pal SK, Hahn AW, Nussenzveig RH, Pond GR, Gupta SV, Wang J, Bilen MA, Naik G, Ghatalia P et al (2018) Characterization of metastatic urothelial carcinoma via comprehensive genomic profiling of circulating tumor DNA. Cancer 124:2115\u20132124","journal-title":"Cancer"},{"key":"4583_CR8","doi-asserted-by":"publisher","first-page":"1830","DOI":"10.1111\/cas.15334","volume":"113","author":"K Nakano","year":"2022","unstructured":"Nakano K, Koh Y, Yamamichi G, Yumiba S, Tomiyama E, Matsushita M, Hayashi Y, Wang C, Ishizuya Y, Yamamoto Y et al (2022) Perioperative circulating tumor DNA enables the identification of patients with poor prognosis in upper tract urothelial carcinoma. Cancer Sci 113:1830\u20131842","journal-title":"Cancer Sci"},{"key":"4583_CR9","doi-asserted-by":"publisher","first-page":"1771","DOI":"10.1111\/cas.14000","volume":"110","author":"Y Hayashi","year":"2019","unstructured":"Hayashi Y, Fujita K, Matsuzaki K, Matsushita M, Kawamura N, Koh Y, Nakano K, Wang C, Ishizuya Y, Yamamoto Y et al (2019) Diagnostic potential of TERT promoter and FGFR3 mutations in urinary cell-free DNA in upper tract urothelial carcinoma. Cancer Sci 110:1771\u20131779","journal-title":"Cancer Sci"},{"key":"4583_CR10","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2020-001406","volume":"9","author":"C Blumendeller","year":"2021","unstructured":"Blumendeller C, Boehme J, Frick M, Schulze M, Rinckleb A, Kyzirakos C, Kayser S, Kopp M, Kelkenberg S, Pieper N et al (2021) Use of plasma ctDNA as a potential biomarker for longitudinal monitoring of a patient with metastatic high-risk upper tract urothelial carcinoma receiving pembrolizumab and personalized neoepitope-derived multipeptide vaccinations: a case report. J Immunother Cancer 9:e001406","journal-title":"J Immunother Cancer"},{"key":"4583_CR11","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1186\/s12885-021-07829-1","volume":"21","author":"B Yang","year":"2021","unstructured":"Yang B, Zhao X, Wan C, Ma X, Niu S, Guo A, Wang J, Wang J, Sun D, Jiao S (2021) Genomic profiling of Chinese patients with urothelial carcinoma. BMC Cancer 21:162","journal-title":"BMC Cancer"},{"key":"4583_CR12","doi-asserted-by":"crossref","first-page":"A48","DOI":"10.1089\/end.2022.0259","volume":"36","author":"T Axelsson","year":"2022","unstructured":"Axelsson T, Syd\u00e9n F, Eisfeldt J, Eriksson Y, Lundberg G, Grahn A, Tham E, Brehmer M (2022) Genetic analysis of focal barbotages a complementary diagnostic tool in upper tract urothelial carcinoma. J Endourol 36:A48\u2013A49","journal-title":"J Endourol"},{"key":"4583_CR13","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1111\/bju.15566","volume":"130","author":"A Grahn","year":"2022","unstructured":"Grahn A, Eisfeldt J, Malm C, Foroughi Asl H, Jaremko G, Tham E, Brehmer M (2022) Genomic profile - a possible diagnostic and prognostic marker in upper tract urothelial carcinoma. BJU Int 130:92\u2013101","journal-title":"BJU Int"},{"key":"4583_CR14","doi-asserted-by":"publisher","first-page":"1160","DOI":"10.3390\/cancers15041160","volume":"15","author":"K Wallander","year":"2023","unstructured":"Wallander K, Haider Z, Jeggari A, Foroughi-Asl H, Gellerbring A, Lyander A, Chozhan A, Cuba Gyllensten O, H\u00e4gglund M, Wirta V et al (2023) Sensitive detection of cell-free tumour DNA using optimised targeted sequencing can predict prognosis in gastro-oesophageal cancer. Cancers (Basel) 15:1160","journal-title":"Cancers (Basel)"},{"key":"4583_CR15","doi-asserted-by":"publisher","first-page":"432","DOI":"10.1038\/s41586-021-03642-9","volume":"595","author":"T Powles","year":"2021","unstructured":"Powles T, Assaf ZJ, Davarpanah N, Banchereau R, Szabados BE, Yuen KC, Grivas P, Hussain M, Oudard S, Gschwend JE et al (2021) ctDNA guiding adjuvant immunotherapy in urothelial carcinoma. Nature 595:432\u2013437","journal-title":"Nature"},{"key":"4583_CR16","doi-asserted-by":"publisher","first-page":"1547","DOI":"10.1200\/JCO.18.02052","volume":"37","author":"E Christensen","year":"2019","unstructured":"Christensen E, Birkenkamp-Demtr\u00f6der K, Sethi H, Shchegrova S, Salari R, Nordentoft I, Wu HT, Knudsen M, Lamy P, Lindskrog SV et al (2019) Early detection of metastatic relapse and monitoring of therapeutic efficacy by ultra-deep sequencing of plasma cell-free DNA in patients with urothelial bladder carcinoma. J Clin Oncol 37:1547\u20131557","journal-title":"J Clin Oncol"},{"key":"4583_CR17","doi-asserted-by":"publisher","first-page":"430","DOI":"10.1038\/s41416-021-01648-8","volume":"126","author":"KS Shohdy","year":"2022","unstructured":"Shohdy KS, Villamar DM, Cao Y, Trieu J, Price KS, Nagy R, Tagawa ST, Molina AM, Sternberg CN, Nanus DM et al (2022) Serial ctDNA analysis predicts clinical progression in patients with advanced urothelial carcinoma. Br J Cancer 126:430\u2013439","journal-title":"Br J Cancer"},{"key":"4583_CR18","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1038\/s41576-018-0071-5","volume":"20","author":"E Heitzer","year":"2019","unstructured":"Heitzer E, Haque IS, Roberts CES, Speicher MR (2019) Current and future perspectives of liquid biopsies in genomics-driven oncology. Nat Rev Genet 20:71\u201388","journal-title":"Nat Rev Genet"}],"container-title":["World Journal of Urology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00345-023-04583-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00345-023-04583-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00345-023-04583-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,12,2]],"date-time":"2023-12-02T12:01:54Z","timestamp":1701518514000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00345-023-04583-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,9,18]]},"references-count":18,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["4583"],"URL":"https:\/\/doi.org\/10.1007\/s00345-023-04583-w","relation":{},"ISSN":["1433-8726"],"issn-type":[{"value":"1433-8726","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,9,18]]},"assertion":[{"value":"1 April 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 August 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 September 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}